Foghorn Therapeutics Inc. (FHTX) Financial Statements
Foghorn Therapeutics Inc. (FHTX) reported trailing twelve-month revenue of $36.7M (up 52.0% year on year) and net income of -$64.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$84.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FHTXFoghorn Therapeutics Inc.Follow FHTX — free
—
Price chart with a free account
- Market cap
- 118.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 1.3 | 19.2 | 34.2 | 22.6 | 30.9 | 36.7 | |
| Gross profit | — | — | — | — | 20.2 | 26.6 | — | |
| Research & development | 57.7 | 80.3 | 105.6 | 109.7 | 94.5 | 85.5 | 78.8 | |
| Operating income | -68.5 | -100.7 | -117.1 | -107.9 | -102.7 | -86.4 | -72.8 | |
| Pre-tax income | -68.8 | -101.3 | -108.9 | -94.2 | -86.6 | -74.3 | -64.6 | |
| Income tax | 0.0 | — | 0.0 | 4.2 | 0.0 | 0.0 | — | |
| Net income | -68.8 | -101.3 | -108.9 | -98.4 | -86.6 | -74.3 | -64.6 | |
| Diluted EPS ($) | -6.23 | -2.73 | -2.62 | -2.34 | -1.58 | -1.18 | -0.98 | |
| Diluted shares (mn) | — | 37.2 | 41.6 | 42.0 | 54.9 | 63.0 | — |
USD millions · SEC XBRL
Foghorn Therapeutics Inc. — questions
- What is Foghorn Therapeutics Inc.'s revenue?
- $36.7M over the twelve months to 2026-06-30, up 52.0% year on year, from its 10-Q and 10-K filings.
- What is Foghorn Therapeutics Inc.'s net income?
- -$64.6M over the twelve months to 2026-06-30.
- What is Foghorn Therapeutics Inc.'s free cash flow?
- -$84.3M over the twelve months to 2026-06-30.
- What are Foghorn Therapeutics Inc.'s diluted earnings per share?
- $-0.98 over the twelve months to 2026-06-30.
Every figure on this page comes from Foghorn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.